



Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-023-02568-1>,
published online 2 October 2023.

<https://doi.org/10.1038/s41591-024-02814-0>

Published online: 19 January 2024

Matthew D. Galsky¹, Siamak Daneshmand, Sudeh Izadmehr¹,
Edgar Gonzalez-Kozlova¹, Kevin G. Chan¹, Sara Lewis, Bassam El Achkar,
Tanya B. Dorff, Jeremy Paul Cetnar, Brock O. Neil, Anishka D'Souza,
Ronac Mamtani, Christos Kyriakopoulos¹, Tomi Jun,
Mahalya Gogerly-Moragoda¹, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly,
Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou,
Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw,
Robert M. Samstein¹, Reza Mehrazin, Nina Bhardwaj¹, Menggang Yu,
Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra¹, Jun Zhu¹,
Sacha Gnjjatic¹, John Sfakianos & Sumanta K. Pal¹

In the version of the article initially published, Diane M. Del Valle (Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA) was missing from the author list; the surname of Amir Horowitz appeared incorrectly (Horwitz); the ClinicalTrials.gov identifier in the Abstract (now listing [NCT03558087](https://clinicaltrials.gov/ct2/show/study/NCT03558087)) was incorrect; and the Acknowledgements were missing additional thanks. The updates now appear in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024